Company Filing History:
Years Active: 2021
Title: Shahrad Daraeikia: Innovator in Antibody Development
Introduction
Shahrad Daraeikia is a prominent inventor based in San Francisco, CA. He has made significant contributions to the field of antibody development, particularly in the fight against viral infections. With a total of 6 patents to his name, Daraeikia is recognized for his innovative approaches to medical science.
Latest Patents
One of his latest patents involves the development of Anti-SARS-Cov-2 antibodies derived from 6nb6. This disclosure provides antibodies and antigen-binding fragments that can be administered to individuals infected or suspected of being infected with a virus. These antibodies are capable of treating or curing the virus and may provide protection for several weeks. Additionally, they can be used to diagnose a SARS CoV 2 infection. Another significant patent is for Anti-SARS-Cov-2 antibodies derived from CR3022, which also offers similar therapeutic and diagnostic capabilities.
Career Highlights
Daraeikia is currently associated with Centivax, Inc., where he continues to push the boundaries of antibody research. His work is crucial in developing treatments that can effectively combat viral infections, particularly in the context of the ongoing global health challenges.
Collaborations
He collaborates with notable colleagues such as Jacob Glanville and I-Chieh Wang, who share his vision of advancing medical science through innovative research.
Conclusion
Shahrad Daraeikia's contributions to antibody development are paving the way for new treatments against viral infections. His innovative patents and collaborations highlight his commitment to improving public health through scientific advancements.